Trial Profile
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects with Crohn's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms CELEST OLE study
- Sponsors AbbVie; AbbVie Germany
- 29 Jan 2024 Last checked against European Clinical Trials Database record.
- 25 Jan 2024 This trial has been completed in Belgium.
- 28 Oct 2020 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020